Estrogen and Raloxifene Stimulate Transforming Growth Factor-β3 Gene Expression in Rat Bone: A Potential Mechanism for Estrogen- or Raloxifene-Mediated Bone Maintenance

Endocrinology

Volumn 137, Issue 5, 1996, Pages 2075-2084

  Yang, Na N ^a   Bryant, Henry U ^a   Hardikar, Sushant ^a   Sato, Masahiko ^a   Galvin, Rachelle J S ^a   Glasebrook, Andrew L ^a   Termine, John D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; RALOXIFENE; TRANSFORMING GROWTH FACTOR BETA3; VITELLOGENIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; FEMUR; GENE EXPRESSION; HORMONE RESPONSIVE ELEMENT; HUMAN; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; PROMOTER REGION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BASE SEQUENCE; BONE AND BONES; CELL DIFFERENTIATION; CELLS, CULTURED; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION; MOLECULAR SEQUENCE DATA; OSTEOCLASTS; OVARIECTOMY; PIPERIDINES; PROMOTER REGIONS (GENETICS); RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0029961569     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.137.5.8612550     Document Type: Article

References (54)

1. Parfitt AM 1994 Osteonal and hemi-osteonal remodeling-the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55:272-286
2. Suda T, Takahashi N, Martin TJ 1992 Modulation of osteoclast differentiation. Endocr Rev 13:66-80
3. Horowitz MC 1993 Cytokines and estrogen in bone: anti-osteoporotic effects. Science 260:626-627
4. Centrella M, Horowitz MC, Wozney JM, McCarthy TL 1994 Transforming growth factor-β gene family members and bone. Endocr Rev 15:27-39
5. Walters MR 1992 Newly identified actions of the vitamin D endocrine system. Endocr Rev 13:719-764
6. Lindsay R, Aitken JM, Anderson JB 1976 Long-term prevention of postmenopausal osteoporosis by estrogen. Lancet 1:1038-1041
7. Barzel US 1988 Estrogens in the prevention and treatment of postmenopausal osteoporosis: a review. Am J Med 85:847-850
8. Kalu DN, Liu CC, Salerno E, Hollis B, Echon R, Ray M 1991 Skeletal response of ovariectomized rats to low and high doses of 17 beta-estradiol. J Bone Miner Res 14:175-187
9. Barrett-Conner E 1992 Hormone replacement and cancer. Br Med Bull 48:345-355
10. Jones CD, Suarez T, Massey EH, Black LJ, Tinsley FC 1979 Synthesis and anti-estrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-napthalenyl] [4-[2-pyrrolidinyl) ethoxy]-phenyl] methanone, methanesulfonic acid salt. J Med Chem 22:962-966
11. Black LJ, Jones CD, Falcone JF 1983 Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 32:1031-1036
12. Gottardis MM, Jordan VC 1987 Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024
13. Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC 1990 Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 50:3189-3192
14. Black LJ, Sato M, Rowley ER, Magee DE, Bendele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
15. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Amaud C, A controlled trial of raloxifene (LY139481) HCI: impact on bone turnover and serum lipid in healthy, postmenopausal women. J Bone Miner Res, in press
16. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240:889-895
17. O'Malley B 1990 The steroid receptor superfamily: more excitement predicted for the future. Mol Endocrinol 4:363-369
18. Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU 1986 An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transtected human cells. Cell 46:1053-1061
19. Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O'Malley BW, Haussler MR 1988 Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241:81-84
20. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL 1988 Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84-88
21. Finkelman RD, Bell NH, Strong DD, Demers LM, Baylink DJ 1992 Ovariectomy selectively reduces the concentration of transforming growth factor β in rat bone: implications for estrogen deficiency-associated bone loss. Proc Natl Acad Sci USA 89:12190-12193
22. Oursler MJ, Cortese C, Keeting P, Anderson MA, Bonde SK, Riggs BL, Spelsberg TC 1991 Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology 129:3313-3320
23. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC 1992 Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257:88-91
24. Sato F, Ouchi Y, Masuyama A, Nakamura T, Hosoi T, Okamoto Y, Sasaki N, Shiraki M, Orimo H 1993 Effects of estrogen replacement on insulin-like growth factor I concentrations in serum and bone tissue and on interleukin 1 secretion from spleen macrophages in oophorectomized rats. Calcif Tissue Int 53:111-116
25. Mundy GR 1991 The effects of TGF-β on bone. In: Clinical Applications of TGF-β. Chichester, Wiley, pp 137-151
26. Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, Rhee L, Mason AJ, Miller DA, Coffey RJ, Moses HL, Chen EY 1988 A new type of transforming growth factor-β, TGFβ-3. EMBO J 7:3737-3743
27. Ogawa Y, Schmidt DK, Dasch JR, Chang R-J, Glaser CB 1992 Purification and characterization of transforming growth factor-β2.3 and -β1.2 heterodimers from bovine bone. J Biol Chem 267:2325-2328
28. Reese JC, Katzenellenbogen BS 1991 Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acids Res 19:6595-6602
29. Kim S-J, Click A, Sporn MB, Roberts AB 1989 Characterization of the promoter region of the human transforming growth factor-β1 gene. J Biol Chem 264:402-408
30. O'Reilly MA, Geiser AG, Kim S-J, Bruggeman LA, Luu AX, Roberts AB, Sporn MB 1992 Identification of an activating transcription factor (ATF) binding site in the human transforming growth factor-b2 promoter. J Biol Chem 267:19938-19943
31. Lafyatis R, Lechleider R, Kim S-J, Jakowlew S, Roberts AB, Sporn MB 1990 Structural and functional characterization of the transforming growth factor β3 promoter. J Biol Chem 265:19128-19136
32. Alvarez JI, Eitelbaum SL, Blair HC, Greenfield EM, Athanasou NA, Ross FP 1991 Generation of avian cells resembling osteoclasts from mononuclear phagoctes. Endocrinology 128:2324-2335
33. Hiura K, Lim S-S, Little SP, Lin S, Sato M 1995 Differentiation dependent expression of tensin and cortactin in chicken osteoclasts. Cell Motil Cytoskeleton 30:272-284
34. Blair HC, Kahn AJ, Crouch EC, Jeffrey JJ, Teitelbaum SL 1986 Isolated osteoclasts resorb the organic and inorganic components of bone. J Cell Biol 102:1164-1172
35. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley J, Martin TJ, Suda T 1988 Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600-2602
36. Chenu C, Pfeilschifter J, Mundy GR, Roodman GD 1988 Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci USA 85: 5683-5687
37. Shah M, Foreman DM, Ferguson MW 1995 Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 108:985-1002
38. Bonewald LF, Dallas SL 1994 Role of active and latent transforming growth factor β in bone formation. J Cell Biochem 55:350-357
39. Oursler MJ 1994 Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. J Bone Miner Res 9:443-452
40. Moses HL, Tucker RF, Leof EB, Coffey RJ, Halper J, Shipley GD 1985 Type-beta transforming growth factor is a growth stimulator and a growth inhibitor. Cancer Cells 3:65-71
41. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B 1987 Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 105:1039-1045
42. Roberts AB, Sporn MB 1992 Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-β. Cancer Surv 14:205-220
43. Flanders KC, Ludecke GL, Engels S, Cissel DS, Roberts AB, Kondaiah P, Lafyatis R, Sporn MB, Unsicker K 1991 Localization and actions of transforming growth factor-betas in the embryonic nervous system. Development 113:183-191
44. Merwin JR, Newman W, Beall LD, Tucker A, Madri JA 1991 Vascular cells respond differently to transforming growth factors beta 1 and beta 2 in vitro. Am J Pathol 138:37-51
45. Nicholson AC, Hajjar DP 1992 Transforming growth factor-beta up-regulates low density lipoprotein receptor-mediated cholesterol metabolism in vascular smooth muscle cells. J Biol Chem 267:25982-25987
46. Grainger DJ, Weissberg PL, Metcalfe JC 1993 Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta. Biochem J 294:109-112
47. Perrella MA, Yoshizumi M, Fen Z, Tsai JC, Hsieh CM, Kourembanas S, Lee ME 1994 Transforming growth factor-beta 1, but not dexamethasone, down-regulates nitric-oxide synthase mRNA after its induction by interleukin-1 beta in rat smooth muscle cells. J Biol Chem 269:14595-14600
48. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasis A, Derynck R, Dickson RB 1987 Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428
49. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W, Schulte-Hermann R 1992 Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci USA 89:5408-5412
50. Moulton BC 1994 Transforming growth factor-beta stimulates endometrial stromal apoptosis in vitro. Endocrinology 134:1055-1060
51. Prehn JH, Bindokas VP, Marcuccilli CJ, Krajewski S, Reed JC, Miller RJ 1994 Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor typo beta confers wide-ranging protection on rat hippocampal neurons. Proc Natl Acad Sci USA 91:12599-12603
52. Pasinetti GM, Nichols NR, Tocco G, Morgan T, Laping N, Finch CE 1993 Transforming growth factor beta 1 and fibronectin messenger RNA in rat brain: responses to injury and cell-type localization. Neuroscience 54:893-907
53. Kraus WL, Katzenellenbogen BS 1993 Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Endocrinology 132:2371-2379
54. Campen CA, Jordan VC, Gorski J 1985 Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus. Endocrinology 116: 2327-2336